fourth quarter

Bank of Baroda share price surges over 50% in a month, jumps 9% today on Q4 profit 

Around 11 AM, Bank of Baroda shares were trading 4.96 per cent higher at Rs 53 apiece as compared to a 0.14 per cent in S&P BSE Sensex

Yes Bank results surprise investors, share price soars 20% to hit circuit; check net profit, income

Yes Bank shares jumped 20 per cent to hit upper circuit at Rs 31.60 apiece on BSE in otherwise weak trade on Thursday. Bank reported a net profit of Rs 2,629 crore for the quarter ended on March 31.

The facility is available on digital channels Yes Mobile and Yes Robot.

HUL share price slips over 5%; analysts say ‘buy’ post Q4 results, check new target prices

The market share of HUL was up by 50bp in 4QFY20 with 80 per cent of portfolio gaining share in the March quarter, a clear indication of resilient performance in an extraordinarily difficult quarter

Sanjiv Mehta, HUL, Hindustan Unilever Limited, Srinivas Phatak, Pradeep Banerjee, Dev Bajpai, Wilhelmus Uijen,

HUL share price falls over 5% in 4 days; is it a time to buy, hold or sell the stocks post Q4 earnings

With relaxation in supply constraints, HUL is now ramping up overall manufacturing output to nearly 80 per cent levels.

Axis Bank share price falls 6% post Q4 result, brokerages turn bullish on the stock with 36% upside

Post quarterly earnings, various research and brokerage firms have maintained 'buy' rating to the Axis Bank stock with an upside of up to 36 per cent in target price.

Glenmark’s consolidated revenue increases by 10.62 per cent to Rs 66447.68 million in FY 14-15

Consolidated revenue in Q4 FY14-15 was Rs 17758.13 million an increase of 4.24 per cent Glenmark Pharmaceuticals announced its results for the fourth quarter and year ended March, 31, 2015. For the fourth quarter ended March

Lupin posts Q4 FY 2014-15 results

Acquires  Brazil-based Medquímica Indústria Farmacêutica Lupin has posted its performance for the fourth quarter and the financial year ending March 31, 2015. Net sales grew by 13.6 per cent to Rs 125,997 million during F

Ajanta Pharma posts Q4 FY ’15 results

Standalone Q4 revenue has shown a growth of 19 per cent and PAT growth of 20 per cent Ajanta Pharma has posted its performance for the fourth quarter and year ended March 31, 2015. The Q4 FY ’15 standalone results show

Advertisement
Income Tax Calculator, Budget 2019, How to Calculate Income Tax

 

Stock Market

Most Read

Advertisement

Budget 2020

Advertisement

Related Articles